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Cervical cancer is the second most common cancer in women worldwide. 
Infection with high-risk human papillomavirus (HPV) types is an essential but 
insufficient risk factor for the development of cervical cancer. The co-factors 
that determine the oncogenic progression of HPV infections are not well 
understood and the progression cannot be reliably predicted by cytology findings 
or HPV DNA test results. Hence, novel and more robust markers are needed. 
Abnormal DNA methylation is now recognized to be responsible for numerous 
human diseases including cancers. The role of methylation in viral life cycle 
II 
although is not yet known, the gene silencing effect of methylation is evident in 
viruses including HPV. Hence, HPV DNA methylation could be involved in 
driving cancer progression. 
In this study, the methylation pattern of the 16 CpG sites within the long 
control region (LCR) of HPV 16 was studied by bisulfite sequencing. 
Methylation patterns of 23 cancer samples, 20 low-grade samples and the 
cervical cancer cell lines CaSki and SiHa were characterized and compared. The 
CpG site at nucleotide position 7270 as predicted from the prototype sequence 
� was found to be absent in majority of our samples (78.3% of cancer samples and 
60.0% of low-grade samples) due to a C > T mutation. This mutation has not 
been reported in previous studies and could be a signature of HPV 16 isolates 
circulating in this region. Alternatively, mutation of this site could be missed if 
sequencing of the original unmodified sequence was not performed as in many 
previous studies. Thus, mutation of this site might be the reason of rare 
methylation of the CpG site at position 7270 reported in previous studies. 
Methylation was found to be much more extensive in CaSki cells than in SiHa 
cells, though they are both cervical cancer-derived cell lines. This diverse 
III 
methylation pattern detected in cancer cell lines was also observed in clinical 
cancer samples. 
Twenty of the 23 (87.0%) cancer samples had methylation of one to 16 
CpG sites. The cancer samples were arbitrarily divided into three groups 
according to the number of methylated CpG sites (me-CpGs) detected. This 
arbitrary grouping was based on our hypothesis that viral DNA methylation 
might account for the development of a proportion of, but not all cancers. 
Therefore, subgroup analysis would avoid possible masking effects. The low-
� level methylation group (zero to five me-CpGs) had preferential methylation in 
the 5' LCR. The medium-level methylation group (six to 10 me-CpGs) and the 
high-level methylation group (11 to 16 me-CpGs) both had highest methylation 
frequency in the promoter region. 
The low-grade group comprised of nine normal cervices and 11 cervical 
intraepithelial neoplasia 1 cases, and they showed a methylation pattern distinct 
from the cancer group. Twelve of the 20 (60.0%) samples of the low-grade 
group had methylation of one to three me-CpGs. The methylation frequency for 
r v 
each CpG site is general lower for the low-grade group, and was mainly 
concentrated at the 5，LCR. 
The methylation frequency of the promoter region of LCR was 
significantly higher in the cancer group (P = 0.0006，Chi-squared test), the 
medium-level (P = 0.0001’ Fisher's exact test) and the high-level (P = 0.0014， 
Fisher's exact test) methylation subgroups when compared respectively to the 
low-grade group. Methylation of the two E2 binding sites (E2BS3 and E2BS4) 
in the promoter region of LCR inhibits E2 binding and hence E2-mediated 
� repression via displacement of binding of transcription factors SPl and TATA-
binding factor will be abolished. This should be beneficial to cancer progression 
as transcription of E6 and E7 oncogenes will be enhanced, which is a key 
mechanism in driving HPV carcinogenesis. 
The methylation pattern of E2BS3 and E2BS4 might have a potential to 
be developed as a novel marker of cancer detection as suggested by their distinct 
methylation frequency in the cancer group and the low-grade group observed in 
this study. However, methylation of E2BS3 and E2BS4 was only observed in 
nine of the 23 cancer samples (39.1%). Therefore, this methylation pattern is not 
V 
adequate to identify all cancer cases. Further studies are required to determine 


































率，而me-CpGs主要集中在5’ L C R � • 
VIII 
相比低度惡性樣本’所有癌症樣本（P = 0.0006，卡方檢驗）、中程度 
甲基化的癌症樣本(P = 0.0001,費雪精確性檢定）和高程度甲基化的癌症樣 
















Table of Contents X 
List of Figures XIV 
List of Tables XVI 
Abbreviations XVII 
Chapter 1 - Introduction 1 
1.1 Biology of HPV 2 
1.1.1 History 2 
1.1.2 Classification 2 
1.1.3 Genome structure 3 
1.2 HPV and cervical cancer 8 
� . 1.2.1 Classification of cervical lesions 8 
1.2.2 Natural history of development of cervical cancer 9 
1.2.3 Risk factors 11 
1.3 Prevention of cervical cancer 12 
1.3.1 Vaccination 12 
1.3.2 Screening 12 
1.3.2.1 Pap test 12 
1.3.2.2 HPV DNA test 13 
1.3.2.3 Methylation pattern as a novel marker 13 
1A Biology of Methylation 14 
1.4.1 Definition 14 
1.4.2 Silencing effect 18 
1.4.3 Roles in normal development 20 
1.5 Methylation and human diseases 20 
1.5.1 Genetic diseases 20 
1.5.2 Cancers 21 
1.5.3 Methylation and oncogenic viruses 23 
X 
1.5.4 Potential of methylation pattern as a novel biomarker of cancer 24 
1.5.5 Epigenetic therapy 25 
1.6 Methylation and HPV 25 
1.6.1 History 25 
1.6.2 Potential roles in transcription regulation of HPV 26 
1.6.3 Viral gene methylation 27 
Chapter 2 - Hypotheses, Objectives and Study Design 28 
2.1 Hypotheses 29 
2.2 Objectives 30 
2.3 Study Design 30 
Chapter 3 - Materials and Methods 34 
3.1 Workflow 35 
3.2 Study subjects 37 
3.2.1 Invasive cervical cancer group 37 
3.2.2 Low-grade group 37 
3.2.3 Cell lines 38 
3.3 DNA extraction 38 
3.4 HPV genotyping 39 
3.5 PGR ofHPV16LCR 39 
3.6 Sequencing of HPV 16 LCR 42 
3.6.1 Purification of PGR products 42 
3.6.2 Cycle sequencing reaction 42 
3.6.3 Purification of cycle sequencing products 43 
3.6.4 Sequencer and data analysis 43 
3.7 Bisulfite modification 43 
3.8 PGR of bisulfite modified LCR 45 
3.9 Cloning 48 
3.9.1 Ligation 48 
3.9.2 Transformation 48 
3.9.3 Colony PGR 49 
3.10 Sequencing of clones 51 
3.10.1 Purification of PGR products 51 
3.10.2 Cycle sequencing reaction 51 
XI 
3.10.3 Purification of cycle sequencing products 52 
3.10.4 Sequencer and data analysis 52 
3.11 Statistical methods 52 
Chapter 4 一 Results 54 
4.1 Sample selection 55 
4.2 HPV16 LCR PGR and sequencing 57 
4.3 Methylation patterns 61 
4.3.1 Cell lines 61 
4.3.2 Cancer group 63 
4.3.2.1 Overview 63 
4.3.2.2 Methylation pattern of the cancer samples 66 ‘ 
4.3.2.3 Methylation pattern of the promoter region 74 
4.3.3 Low-grade group 76 
4.3.3.1 Overview 76 
4.3.3.2 Methylation pattern of the low-grade samples 79 
4.3.4 Comparison of the methylation patterns of the cancer samples 84 
and the low-grade samples 
Chapter 5 一 Discussion 95 
5.1 Sequence variations of HPV16 LCR 96 
5.2 Methylation patterns of CaSki and SiHa cell lines 98 
5.3 Methylation pattern of the cancer samples 99 
5.4 Methylation pattern of the low-grade samples 100 
5.5 Comparison of methylation patterns of the cancer samples and the 101 
low-grade samples 
5.5.1 Promoter region in 3，LCR 102 
5.5.1.1 SPl binding site 102 
5.5.1.2 E2BS3 and E2BS4 103 
5.5.2 Silencer region 104 
5.5.3 Enhancer region in central LCR 105 
5.5.4 CpG sites within 5’ LCR 106 
5.6 Role of methylation in HPV16 107 
5.7 Potential as novel biomarker 108 
5.8 Conclusions 109 
XII 
te. 产 D s e gel tki'XTophm-^m ci HPV WH 
• ^ H H ^ ^ i y ^ ^ ^ S gel 功s of a 1 and A t ！ 參 
^ " 卞 ” B B B Blmpi^ ^^ ^^  
拙bcf ofmihylmd i：^ niies m the cancer 
钱傲树(》（饭'rnHhylauDfi tkquemy of each CpG utc m tlE^ 7i) 
_ w 轻 ^ ^ siib丨ecfjO . 
醒 》 Q f m / h y m r n li'c^aencY ^t'eacb CpG site i r u i ^ T i : 
ineihvmioit) 广 - B K 
• l ^ ^ l S ^ K f i C ^ B m p h m t .^f ead^ C p d nitc in tm T j ^ M B B S ^ 
, ’ of nmhyrnion htqimKf ^ftmli CnO site in te 73' • 
. THWifel , c m ^ t t fTuup ？bigb'kvel tiieihyi&to) ^ ^ ‘ �- • • " • H l j 
, ! 4 7 咖 M a d 械 patterr of the CpG s t o wiihm the 辦 m 咖 7$ %r, : • 
List of Figures 
Figure 1.1 Genome structure of HPV 6 
Figure 1.2 Schematic representation of the four E2 binding sites 7 
within the LCR 
Figure 1.3 Natural history of development of cervical cancer 10 
Figure 1.4 DNA methylation 17 
Figure 1.5 Silencing effect of DNA methylation 19 
Figure 2.1 Bisulfite modification 32 
Figure 2.2 Interpretation of sequencing results 33 
Figure 3.1 Work flow 36 ‘ 
Figure 4.1 Number of samples attempted at each stage 56 
Figure 4.2 Sequencing result of C > T mutation at nucleotide 59 
position 7270 
Figure 4.3 Agarose gel electrophoresis of HPV 16 LCR PGR products 60 
Figure 4.4 Agarose gel electrophoresis of A1 and A2 PGR products 64 
of the cancer samples 
Figure 4.5 Number of methylated CpG sites in the cancer samples 67 
Figure 4.6A Box plot of methylation frequency of each CpG site in the 70 
cancer group (all subjects) 
Figure 4.6B Box plot of methylation frequency of each CpG site in the 71 
cancer group (low-level methylation) 
Figure 4.6C Box plot of methylation frequency of each CpG site in the 72 
cancer group (medium-level methylation) 
Figure 4.6D Box plot of methylation frequency of each CpG site in the 73 
cancer group (high-level methylation) 
Figure 4.7 Methylation pattern of the CpG sites within the promoter 75 
region in the cancer samples 
Figure 4.8 Agarose gel electrophoresis of A2 first-round PCR 77 
products of low-grade samples 
Figure 4.9 Agarose gel electrophoresis of A2 second-round PCR 78 
products of low-grade samples 
XIV 
Figure 4.10 Number of methylated CpG sites of the low-grade 81 
samples 
Figure 4.11 Number of low-grade samples with methylation at each 82 
CpG site 
Figure 4.12A Comparison of methylation frequency of each CpG site in 91 
the cancer group (all subjects) and the low-grade group 
Figure 4.12B Comparison of methylation frequency of each CpG site in 92 
the cancer group (low-level methylation) and the low-
grade group 
Figure 4.12C Comparison of methylation frequency of each CpG site in 93 
the cancer group (medium-level methylation) and the low-
grade group 
Figure 4.12D Comparison of methylation frequency of each CpG site in 94 
the cancer group (high-level methylation) and the low-
grade group 
XV 
List of Tables 
Table 3.1 Primer sequences of HPV 16 LCR PGR 41 
Table 3.2 Primer sequences of modified HPV 16 LCR PGR 47 
Table 3.3 M-13 primer sequences of colony PCR 50 
Table 4.1 Percentage of clones containing methylation at each CpG site 62 
in CaSki and SiHa cell lines 
Table 4.2 Number of A1 and A2 clones sequenced for each cancer 65 
sample 
Table 4.3 Percentage of clones containing methylation at each CpG site 68 
in the cancer samples 
Table 4.4 Percentage of clones containing methylation at each CpG site 83 
in the low-grade samples 
Table 4.5 Comparison of methylation frequency in the cancer samples 86 
and the low-grade samples 
Table 4.6A Comparison of methylation frequency in 5' LCR in the 87 
cancer samples and the low-grade samples 
Table 4.6B Comparison of methylation frequency in enhancer region in 88 
the cancer samples and the low-grade samples 
Table 4.6C Comparison of methylation frequency in silencer region in 89 
the cancer samples and the low-grade samples 
Table 4.6D Comparison of methylation frequency in promoter region in 90 





ASCH atypical squamous cells cannot exclude HGSIL 
ASCUS atypical squamous cells of undetermined significance 
bp base pair 
BWS Beckwith-Wiedemann Syndrome 
C cytosine 
CDKN2A cyclin-dependent kinase inhibitor 2A 
CDKN2B cyclin-dependent kinase inhibitor 2B 
CHDl chromodomain-helicase-DNA-binding protein 
CIN cervical intraepithelial neoplasia 
CpG cytosine-phosphate-guanine 
C/EBP CCAAT/ enhancer binding protein 
DAPKl death-associated protein kinase 1 
DNA deoxyribonucleic acid 
DNMT DNA methyltransferase 
DNTP deoxynucleoside triphosphate 
EBV Epstein-Barr virus 
E2BS E2 binding site 
FDA Food and Drug Administration 
g gravitational acceleration 
G guanine 
HBV hepatitis B virus 
HDAC histone deacetylase 
HGSIL high-grade squamous intraepithelial lesion 
HPV human papillomavirus 
hr hour 
ICF immunodeficiency, centromere instability and facial anomalies 
ICTV International Committee on Taxonomy of Viruses 
IGF2 insulin-like growth factor 2 
LB Luria-Bertani 
LCR long control region 





LINE long interspersed nuclear element 
LMPl latent membrane protein 1 j 
me-CpG methylated CpG site 
MeCP2 methylated-CpG binding protein 2 
MGMT O-6-methylguanine-DNA methyltransferase 
min minute 
mL millilitre 
MLHl mutL homolog 1 
mM millimole 
MSP methylation-specific PCR 
ng nanogram 
NFl nuclear factor 1 
N-terminal amino-terminal 
Oct-1 octamer transcription factor 1 
Pap Papanicolaou 
PCR polymerase chain reaction 
PEF-1 papillomavirus enhancer binding factor 1 
PV papillomavirus 
RARB retinoic acid receptor beta 
RASSFl ras association domain-containing protein 1 
RB retinoblastoma 
RNA ribonucleic acid 
SAM S -adenosyl-L-methionine 
s e e squamous cell carcinoma 
sec second 
S.O.C. super optimal broth 
SPl specificity protein 1 
T thymine 
taq thermos aquaticus 
TEF-1 transcriptional enhancer factor 1 
U uracil 
VLP virus-like particle 
YYl yin and yang 1 
XVIII 
3’ 3 prime direction 
5’ 5 prime direction 










1.1 Biology of HPV 
1.1.1 History 
Papillomavirus (PV) is ubiquitous in the animal kingdom including 
mammals, birds and even reptiles. Human papillomavirus (HPV) is a very 
common virus and is now recognized as the major aetiology of cervical cancer. 
It is also found in cancers of the anus, vagina, vulva, penis and the head and ‘ 
neck region. The study of HPV began in the 1960s (Almeida and Goffe, 1965; 
Crawford, 1965; Klug and Finch, 1965). However, the lack of appropriate cell 
culture systems has hampered the progress in studying the virus until the advent 
of molecular biology techniques in the 1970s. HPVl is the first HPV with its 
full genome sequenced, followed by HPV6 and HPV 16 (Danos et al.，1982; 
Schwarz et al., 1983; Seedorf et al., 1985). Nowadays, more than 100 types of 
HPV have been characterized. 
1.1.2 Classification 
Papillomavirus was once belonged to the Papovaviridae family together 
with the polyomavirus. In 1998，it was classified by International Committee 
on Taxonomy of Viruses (ICTV) as an individual family, the Papillomaviridae 
(de Villiers et al., 2004). The classification of HPV is based on the LI sequence 
2 
as it is the most conserved gene within the genome. A new HPV type is defined 
as having the LI sequence differs from the sequence of any existing HPV types 
by at least 10%. Subtypes and variants are defined as having sequence 
difference between 2 - 1 0 % and less than 2%, respectively (de Villiers et al.， 
2004). Papillomavirus is also categorized into 16 genera and 44 species. 
To date, more than 100 different types of HPV have been identified. 
Over 40 of them infect the genital tract, which can be categorized into high-risk 
and low-risk types according to their association with cervical cancer 
(Woodman et al., 2007). HPV 16 and 18 are the most prevalent high-risk types 
� and are together associated with more than 70% of all cervical cancers. HPV6 
and 11 are the most common low-risk types and are the cause of around 90% of 
genital warts (Schiffman et al., 2007). 
1.1.3 Genome structure 
HPV is a small, circular, double-stranded DNA virus. The HPV genome 
is around 8000 bp in size and codes for eight genes, which include two late 
genes and six early genes (Doorbar, 2006) (Figure 1.1). LI and L2 are the two 
late proteins that make up the protein coat of the viral capsid. E l and E2 
proteins regulate viral DNA transcription and replication. E4 is thought to be 
3 
involved in virion release by disrupting keratin filament formation in 
differentiating keratinocytes (Mcintosh et al., 2010). E5 is suggested to be 
important in the early stage of infection. It has been shown to stimulate cell 
growth by interacting with the epidermal growth factor receptor and prevent 
apoptosis following DNA damage (Hwang et al., 1995; Zhang et al., 2002). E6 
and El are the major oncoproteins which interact with and degrade tumour 
suppressor proteins p53 and RB, respectively. This leads to abrogation of 
apoptosis and hence uncontrolled proliferation (zur Hausen, 2002). A non-
coding regulatory region called the long control region (LCR) is located 
between E6 and LI. 
HPV 16 LCR is around 850 bp in size and can be divided into 5', central 
and 3' segments. An enhancer is located in the central LCR. It is a cluster of 
binding sites of more than 20 cellular transcription factors, including NFl , API, 
YYl, TEF-1 and Oct-1 (Bhattacharjee and Sengupta, 2006b). The 3’ LCR 
contains a binding site of the cellular transcription factor SPl , the origin of 
replication and the early promoter p97, which controls the transcription of E6 
and E7 oncogenes. p97 is regulated by the cellular transcription factors 
contained in the enhancer and the viral transcription factor E2. Without the 
enhancer, p97 of HPV 16 has only moderate activity by itself (Bernard, 2002). 
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A silencer, which contains binding sites for repressors, is found between the 
enhancer and the promoter. 
I 
Four highly conserved palindromic E2 binding sites (E2BSs) are found 
within the LCR of high-risk HPV genomes (Figure 1.2). One located in the 5' 
LCR, one flanked by the silencer and the origin of replication and two in the 
promoter region (Bernard, 2002). E2 binds as a dimer to the E2BS consensus 
sequence ACCNeGGT (Tommasino, 1997). E2 acts primarily as a repressor of 
the p97 through negative feedback control mechanism. E2 also takes part in 
replication by recruiting El helicase to the viral origin of replication (Frattini 
� and Laimins, 1994). 
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Figure 1.1 Genome structure of HPV 
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Figure 1.2 Schematic representation of the four E2 binding sites within LCR 
LCR is divided into 5，，central and 3’ segments. The nucleotide positions of the four 
E2 binding sites are shown. One is found within the 5’ LCR, one flanked by the 
silencer and the origin of replication and two in the promoter region, just upstream of 
the transcription start site (represented by the red arrow). 
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1.2 HPV and cervical cancer 
The role of HPV in causing human anogenital cancers was suggested in 
the 1970s (zur Hausen, 1977). HPV is found in virtually all cervical cancers 
(Bosch et al.，1995) and is now a well established causative agent of the cancer. 
Cervical cancer is the second most common cancer in women worldwide. 
About 500,000 new cases of cervical cancer occur around the world every year, 
with over 80% of which happen in the developing countries (Cutts et al., 2007). 
In Hong Kong 2008，it ranked 10 among women cancers and caused 120 deaths 
(Hong Kong Cancer Registry, 2008) 
1.2.1 Classification of cervical lesions 
Cervical abnormalities can be categorized into cervical intraepithelial 
neoplasia (CIN) 1，2 and 3, which represent mild dysplasia, moderate dysplasia 
and severe dysplasia or carcinoma in situ, respectively. The grading is based on 
the thickness of cervical epithelium occupied by abnormal cells (Buckley et al., 
1982). 
Cervical lesions can also be classified by the Bethesda System, which is 
a system developed for reporting results of cervical cytology. The first 
workshop was held in 1988 and the system was modified in 1991 and 2001. 
8 
Under the 2001 Bethesda System, squamous cell abnormalities are classified as 
atypical squamous cells of undetermined significance (ASCIIS), atypical 
squamous cells cannot exclude HGSIL (ASCH), low-grade squamous 
intraepithelial lesion (LGSIL), high-grade squamous intraepithelial lesion 
(HGSIL) and squamous cell carcinoma (SCC) (Solomon et al.’ 2002). LGSIL 
encompasses mild dysplasia and CIN 1, whereas HGSIL includes 
moderate/severe dysplasia, CIN 2/3 and carcinoma in situ. 
1.2.2 Natural history of development of cervical cancer 
Cervical cancer usually arises from a ring of mucosa called the cervical 
transformation zone. Initial infection usually takes five to 10 years to progress 
to CIN 2/3 and another five to 10 years for cancer to develop (Schiffman et al., 
2007) (Figure 1.3). Most women have been infected with one or more types of 
HPV during their sexual life (Baseman and Koutsky, 2005). Fortunately, vast 
majority of HPV infections are transient and are cleared by the host immune 
system within six to 18 months (Plummer et al., 2007). A small proportion of 
infections will establish persistent infection and may further progress. Among 
all initial HPV infections, only about 10% will progress to CIN 1，1% to CIN 
2/3，and 0.1% will eventually progress to cervical cancers. There is also a great 
chance of regression along the process (Schiffman et al., 2007). 
9 
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Figure 1.3 Natural history of development of cervical cancer 
Majority of HPV infections are transient and are cleared within 6 - 1 8 
months. Initial infections take 5 - 1 0 years to establish high-grade dysplasia 
(CIN 2/3) and another 5 - 1 0 years to develop invasive cancer. Infections 
may progress to CIN 2/3 without going through CIN 1. 
CIN: cervical intraepithelial neoplasia 
I ： > represents progression 
represents regression 
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1.2.3 Risk factors 
Infection with high-risk HPV types is an essential but insufficient risk 
factor for the development of cervical cancer. HPV 16 is responsible for around 
half of all cervical cancers and is most strongly associated with cervical 
squamous cell carcinoma. HPV 18 accounts for around 20% of cervical cancers 
and is the most prevalent type found in cervical adenocarcinoma (Munoz et al., 
2003). 
Host factors such as genetic predisposition, smoking, oral 
contraceptives and immunity level may play a role but should not be the sole 
determinant of transient infection or cancer progression. HPV viral gene 
integration has long been recognized as an event involved in HPV 
transformation (el Awady et al., 1987; Jeon et al., 1995). Integration usually 
leads to the disruption of E2 gene and loss of its negative feedback control of 
E6 and E7 oncogenes expression and hence should be beneficial to HPV 
transformation. However, episomal or concomitant forms of HPV are also 
found in invasive cancer specimens (Cullen et al., 1991; Matsukura et al., 1989). 
This suggests that HPV integration is not a prerequisite of cancer progression. 
The role of epigenetic events in the progression of cervical lesions is being 
studied in recent years but with inconclusive results. Therefore, the co-factors 
11 
that determine the oncogenic progression of HPV infections are still not well 
understood. 
1.3 Prevention of cervical cancer 
1.3.1 Vaccination 
Two HPV LI virus-like particle (VLP) vaccines are now available. 
Gardasil®, marketed by Merck; and Cervarix®, marketed by GlaxoSmithKline 
both protect against HPV 16 and 18 infections. Gardasil® in addition protects 
against HPV6 and 11 infections. Although HPV 16 and 18 are together 
associated with around 70% of cervical cancers, there are at least 13 other 
oncogenic HPV types that can potentially cause cervical cancer. 
1.3.2 Screening 
1.3.2.1 Pap test 
The Papanicolaou (Pap) test is the primary screening method for 
cervical abnormalities. It is named after George Papanicolaou in 1949 
(Papanicolaou, 1949). It has significantly reduced the incidence and mortality 
of cervical cancer. However, Pap test is not sensitive enough (Cantor et al., 
2008). Errors may occur when cells are not collected from the cervical 
12 
transformation zone or abnormal cells are missed or misinterpreted. Besides, 
women in certain cultures do not accept the screening process (Scarinci et al., 
2010). 
1.3.2.2 HPV DNA test 
The detection of high-risk HPV DNA by advanced molecular 
techniques has a high sensitivity. However, majority of the infections are only ‘ 
transient and therefore detection of high-risk HPV types does not necessarily 
reflect the subject has a higher risk of developing cervical cancer. 
1.3.2.3 Methylation pattern as a novel marker 
The progression of cervical lesions cannot be reliably predicted by 
cytology findings or HPV DNA test results. Hence, novel and more robust 
markers are needed. An ideal marker is one that is non-invasive, highly 
sensitive and specific and can be tested on a high-throughput platform. 
Recently, the study of methylation markers of cancers has become the 
focus of intense research (Geddert et al., 2010; Ibrahim et al., 2010; Kawakami 
et al., 2010; Missaoui et al., 2010; van den Berg et al., 2010). For cervical 
cancer, majority of the studies have focused on methylation of host genes, 
including tumour suppressor genes, DNA repair genes and genes involved in 
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regulation of cell cycles (Apostolidou et al., 2009; Lai et al., 2008; Wisman et 
al., 2006). Methylation of a wide range of host genes in all cervical lesion 
grades is being studied and compared. A recent review summarized all the 
studies that have been conducted in the area (Wentzensen et al., 2009). The 
most commonly studied host genes include DAPKl, RASSFl, CDHl, MGMT 
and RARE. However, methylation frequency of the same gene in the same 
lesion grade was found to be significantly different among individual studies 
(Wentzensen et al., 2009). Therefore, no one single host gene can be readily 
used as the target of a methylation test for cervical cancer. 
1.4 Biology of Methylation 
1.4.1 Definition 
DNA methylation, together with histone modification and microRNA-
mediated regulation are known as epigenetic events, which are defined as 
inheritable and reversible events that alter gene expression without changes in 
DNA sequence (Momparler, 2003). 
The fundamental unit of chromosomes is nucleosome, which consists of 
146 bp of DNA wrapping around a group of eight histories. The N-terminal 
tails of histories are subjected to post-translational modifications including 
14 
methylation, acetylation and phosphorylation (Sawan et al., 2008). MicroRNA 
is the most recently recognized type of epigenetic mediator and has been shown 
to participate in several oncogenic signalling pathways (Calin and Croce, 2007). 
DNA methylation was first discovered in the 1940s and is found to be 
the most common covalent modification of DNA in eukaryotes (Luczak and 
Jagodzinski, 2006). It is the transfer of a methyl group, from a universal methyl 
donor called S-adenosyl-L-methionine (SAM), to the cytosine residue of 5'-
cytosine-guanine-3，(CpG) dinucleotides along DNA sequence (Figure 1.4). 
The process is catalyzed by enzymes called DNA methyltransferase (DNMT), 
� which can be maintenance or de novo. Maintenance DNMTl binds methyl 
groups to hemi-methylated DNA during replication, whereas de novo 
DNMT3A and DNMT3B add methyl groups to CpG sites of unmethylated 
DNA (Luczak and Jagodzinski, 2006). 
In mammals, CpG sites are primarily located in regions called the CpG 
islands and in promoters or first exon sequences. CpG islands have different 
definitions, one of which defines CpG islands as regions of at least 200 bp with 
GC content more than 50% and the observed number of CpG sites more than 
60% of the expected value (Gardiner-Garden and Frommer, 1987). About half 
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of the human gene promoter regions contain CpG islands with sizes up to 
several kbs (Bird, 1986). 
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Figure 1.4 DNA methylation 
DNA methylation is the transfer of a methyl group to the cytosine residues of 
CpG sites and is catalyzed by enzymes called DNA methyltransferase (DNMT). 
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1.4.2 Silencing effect 
Methylation in general leads to repression of transcription (Eden and 
Cedar, 1994). For transcription to occur, transcription factors have to bind to 
their specific binding sites within enhancers or promoters (Figure 1.5). This 
then promotes the binding of RNA polymerase and hence transcription will be 
initiated. When DNA is methylated, binding is inhibited by direct blockage or 
by recruitment of methylated-CpG binding proteins, such as MeCPl and 
MeCP2 (Luczak and Jagodzinski, 2006). Besides, methylation also recruits 
histone deacetylase (HDAC) which elicits a more tightly packed chromatin 
� structure unfavourable for transcription (Costello and Plass, 2001). 
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Figure 1.5 Silencing effect of DNA methylation 
DNA methylation inhibits transcription by direct blockage of transcription factors 
binding or by recruitment of methylated DNA binding proteins. 
CH3： methyl group 
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1.4.3 Roles in normal development 
DNA methylation is essential in normal development of humans and 
other eukaryotes. It has been shown that deletion of any DNMT is lethal in 
mice (Okano et al., 1999). Methylation is involved in the inactivation of one of 
the X chromosomes in female cells, which ensures equal expression level of the 
X chromosome gene in male and female cells (Goto and Monk, 1998). It also 
has roles in processes including regulation of gene expression and chromatin 
structure, genomic imprinting and defence mechanisms. 
1.5 Methylation and human diseases 
Methylation in humans is a tightly regulated process and methylation 
patterns in somatic cells are highly conservative. The importance of 
methylation is highlighted by the various diseases caused by deregulation of 
methylation or disruption of its machinery. 
1.5.1 Genetic diseases 
ICF (immunodeficiency, centromere instability and facial anomalies) 
syndrome is caused by mutations of DNMT3B. It is a rare autosomal recessive 
disorder characterized by various immunodeficiencies. Mutation of the 
methylated DNA binding protein MeCP2 leads to Rett syndrome, which is an 
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X-linked disorder characterized by mental disorder and autistic behaviour. 
Beckwith-Wiedemann Syndrome (BWS) is an overgrowth disorder caused by 
loss of imprinting of the insulin-like growth factor 2 (IGF2) (Hitchins and 
Moore, 2002). 
1.5.2 Cancers 
The study of association between epigenetics and human cancers has 
become a hot topic in cancer research in recent years. Its importance is 
reflected by the development of the human epigenome project (Esteller, 2006; 
Jones and Martienssen, 2005). Cancer was once viewed as a disease primarily 
� caused by genetic mutations. It is now recognized that abnormal epigenetic 
events are also responsible for carcinogenesis. Aberrant epigenetic events are 
sometimes found to precede genetic mutations, indicating that they are not 
always a consequence of mutations (Sawan et al., 2008). In fact, deregulated 
epigenetic events are associated with virtually every step of carcinogenesis. 
The first report describing the association between altered DNA 
methylation pattern and cancers was published in 1983 (Feinberg and 
Vogelstein, 1983). Too much (hyper-) or too little (hypo-) methylation both 
may contribute to cancer development. Hypomethylation is usually genome 
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wide and hypermethylation is found to be gene-specific (Feinberg and Tycko, 
2004). 
Elevated expression of DNMT is found in various cancers including 
cancers of the colon, the breast and the stomach (Luczak and Jagodzinski, 
2006). Hypermethylation has been found in the promoter regions of numerous 
tumour suppressor genes including cyclin-dependent kinase inhibitor 2A 
(CDKN2A) and 2B (CDKN2B), E-cadherin, retinoblastoma (RB) and human 
mismatch repair gene MLHl . Hypermethylation represses the expression of the 
tumour suppressor genes and hence favours the development of malignant 
� phenotype. Hypermethylation has been shown to enhance carcinogen binding. 
It also increases mutation rate due to altered repair efficiency, differential rate 
of spontaneous deamination and cell division (Robertson and Jones, 2000). 
Consequently, CpG sites have been lost during evolution and are highly 
underrepresented in vertebrate genomes (Sved and Bird, 1990). Methylated 
cytosine is two to three times more prone to spontaneous deamination than 
unmethylated cytosine (Shen et al., 1994). This leads to a high rate of transition 
mutation (usually C to T) and results in T-G mismatch after DNA replication. It 
has been suggested that methylated CpG may be the origin of one-third of all 
transition mutations in human diseases (Jones et al.，1992). 
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On the other hand, hypomethylation leads to chromosomal instability 
and activation of cellular proto-oncogenes (Ehrlich, 2002). Hypomethylation of 
retrotransposons destabilizes the genome by insertional mutagenesis and 
recombination between non-allelic repeats. Hypomethylated long interspersed 
nuclear elements (LESfEs) is found in colon cancer and chronic lymphocytic 
leukeamia (Carnell and Goodman, 2003). Loss of imprinting is also a 
consequence of hypomethylation. For example, insulin-like growth factor 2 
(IGF2) is transcribed only from one allele whereas the other is imprinted by 
methylation in normal cells. Hypomethylation causes expression of the 
normally imprinted allele and promotes growth of cancer cells. (Vu et al.， 
2003). 
1.5.3 Methylation and oncogenic viruses 
Around 20% of all human cancers are associated with viruses. Various 
viral oncoproteins are reported to interfere with the methylation machinery. 
Hypermethylation of viral genes is identified in viruses including human 
papillomavirus (HPV), Epstein-Barr virus (EBV) and hepatitis B virus (HBV) 
(Paschos and Allday, 2010). The role of methylation in viral life cycles is not 
yet known. The possible roles are evasion of host immune system or 
establishment of latent infection, which are crucial events in carcinogenesis. 
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EBV is associated with several human cancers including 
nasopharyngeal carcinoma and Burrkitt's lymphoma (Young and Rickinson, 
2004). The viral oncoprotein of EBV, latent membrane protein 1 (LMPl) has 
been shown to activate DNMT, which leads to an increased level of DNA 
methylation and downregulation of E-cadherin (Tsai et al., 2002). E-cadherin is 
a tumour suppressor gene which affects tumour invasiveness and is frequently 
found to be repressed by methylation in human cancers (Onder et al., 2008). 
Overexpression of HBV X antigen also results in downregulation of E-cadherin 
and pl6INK4A through interactions with DNMT (Liu et al., 2006). 
1.5.4 Potential of methylation pattern as a novel biomarker of cancer 
Methylation pattern in no doubt has a potential to be a novel biomarker 
of cancers. Hypermethylation of most genes is rare in healthy individuals. 
Another important feature of DNA methylation is that it is tissue and tumour 
type specific (Esteller et al., 2001). Methylation patterns may also provide 
prognostic information by predicting loss of function of important tumour 
suppressor genes. Moreover, DNA methylation is chemically stable and 
relatively easy to assess. Non-invasive assessment can be done on cells carried 
in body fluid. 
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1.5.5 Epigenetic therapy 
Epigenetic machinery is an attractive therapy target because of its 
reversibility in contrast to genetic mutations. DNA methylation machinery is 
the most studied epigenetic target. Inhibition of DNMT has been shown in vitro 
to reverse aberrant DNA methylation of tumour suppressor genes and restore 
normal gene expression in cancer cells (Robertson and Jones, 2000; Silverman 
et al., 2006). The most potent DNMT inhibitors are 5-Aza-cytidine (5-Aza-CR) 
and 5-Aza-2'-deoxycytidine (5-Aza-CdR). They are nucleoside analogues 
which induce DNMT inhibition after incorporation into DNA. 5-Aza-CR and 
� 5-Aza-CdR have been approved by the Food and Drug Administration (FDA) 
in the USA as treatment of myeloid malignancy (Yang et al., 2010). 
1.6 Methylation and HPV 
1.6.1 History 
Methylation of HPVl and cotton tail rabbit papillomavirus was reported 
more than 25 years ago (Burnett and Sleeman, 1984; Wettstein and Stevens, 
1983) but the phenomenon has not been systematically investigated until recent 
years. Methylation has been found in both low-risk and high-risk HPV types 
(Kalantari et al., 2004). Similar to that in humans (Sved and Bird, 1990), CpG 
25 
sites are underrepresented in genomes of different HPV types including HPV6, 
11, 16, 18，31 and 45. A total of 110 CpG sites are found in the HPV 16 genome, 
which is less than 30% of the expected value (Badal et al., 2003). This may 
imply adverse functional consequences of methylated CpG in the biology of 
genital HPV. 
1.6.2 Potential roles in transcription regulation of HPV 
There is evidence that the gene silencing effect of methylation is also 
present in HPV. CaSki and SiHa are two cervical cancer cell lines which 
contain around 600 copies and one copy of HPV 16 genome, respectively. 
However, their transcription levels are found to be similar despite the large 
difference in viral genome copies (Baker et al., 1987). This is proposed to be 
due to the extensive methylation of HPV genomes harboured in CaSki. Besides, 
methylation of HPV 16 E2BS has been shown to prevent E2 binding (Kim et al., 
2003; Thain et al., 1996) and was suggested to be involved in HPV 
carcinogenesis (Bhattacharjee and Sengupta, 2006a). Moreover, oncoprotein E7 
was shown to modulate DNMTl levels and reduce the level of E-cadherin 
(Laurson et al., 2010). 
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1.6.3 Viral gene methylation 
A few studies have examined patterns of HPV viral gene methylation in 
cervical lesions (Badal et al., 2004; Badal et a l , 2003; Brandsma et al., 2009; 
Ding et al., 2009; Kalantari et al., 2004; Rajeevan et a l , 2006). The focus is 
usually on LI or LCR of HPV 16 or 18. LCR is the most commonly targeted 
region as it contains the early promoter and also binding sites of numerous vital 
transcription factors. CpG sites are contained within some of the binding sites 
including SPl and the four E2BSs. However, the results from different studies 
were not consistent. One study on HPV 16 LCR showed that methylation 
- frequency decreased with progression of cervical lesions (Badal et al., 2003). 
Another similar study found out that methylation was lowest in dysplasia, 
intermediate in asymptomatic specimens and highest in cancers (Kalantari et al., 
2004). Yet another study stated that methylation frequency increased with the 
progression of cervical lesions (Ding et al., 2009). Hence, the results are not yet 








Infection with high-risk HPV types is essential for the development of 
cervical cancer. However, the virus alone is not sufficient to cause the disease. 
Overexpression of HPV oncogenes E6 and E7 is believed to be crucial in 
transformation (DeFilippis et al., 2003). This can be caused by HPV viral gene 
integration, which results in disruption of the E2 gene and loss of its negative 
feedback control of E6 and E7 oncogenes expression. However, additional 
mechanism must exist as HPV integration was found not to be a prerequisite of 
causing cervical cancer (Matsukura et al., 1989). DNA methylation is 
� supported by evidence to have regulatory role in HPV. Methylation of E2 
binding sites (E2BSs) has been shown to inhibit the binding of E2 in vitro and 
hence could be an alternative mechanism leading to overexpression of viral 
oncogenes E6 and E7 (Kim et al., 2003). 
The hypotheses of this study are: firstly, methylation of HPV viral 
genome has a crucial role in the progression of cervical lesions; secondly, 
methylation pattern varies among different lesion grades and therefore could be 
used as a prognostic marker for the development of cervical cancer. 
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2.2 Objectives 
1. To delineate the LCR sequences of HPV 16 genomes harboured in 
CaSki and SiHa cell lines and clinical samples. 
2. To characterize the methylation patterns of the 16 CpG sites within the 
LCR of HPV 16 genomes harboured in CaSki and SiHa cell lines. 
3. To delineate and compare the methylation patterns of the 16 CpG sites 
within the LCR of HPV 16 genomes harboured in cancer and low-grade 
lesions. 
4. To evaluate the potential of using methylation pattern as a novel 
� biomarker for the development of cervical cancer. 
2.3 Study Design 
This cross-sectional study aimed at characterizing the methylation 
pattern of the 16 CpG sites within the LCR of HPV 16 genome. Five of the CpG 
sites are located in the enhancer region, five in the promoter region, five in the 
5’ LCR and one flanked by the silencer and the origin of replication. Two 
patient groups, those with invasive cancers and those with low-grade cervical 
lesions, were included in this study. All samples examined were shown to have 
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HPV 16 as the only HPV type present. Cervical cancer cell lines, CaSki and 
SiHa, were also studied. 
The LCR was amplified and sequenced to look for mutations of the 
CpG sites and nucleotide variations within the LCR. Bisulfite sequencing with 
cloning was done to study methylation pattern (Frommer et al., 1992). The 
samples were first subjected to bisulfite modifications, which altered 
unmethylated cytosines to uracils, with methylated ones unaffected (Figure 2.1). 
The modified LCR was then amplified in two segments (Al and A2) as the 
LCR was too long for amplification due to the introduction of nicks by the 
� modification process. The two amplicons was cloned into Escherichia coli 
plasmids. At least 15 clones of each amplicon were sequenced for each sample 
to account for heterogeneity of methylation pattern. The number of clones to be 
sequenced was decided by the observation that 15 clones were adequate to 
represent methylation pattern of individual samples. The methylation pattern 
was revealed by the sequencing results. A thymine will be resulted at the 
position where an unmethylated cytosine is situated. Methylated cytosines will 
remain unchanged after sequencing (Figure 2.2). The methylation patterns of 
the two groups were then compared. 
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Figure 2.1 Bisulfite modification 
Bisulfite modification deaminates umnethylated cytosines to uracils and thymines will 
be resulted after sequencing. Methylated cytosines are protected from this modification. 
C represents uiimethylated cytosine 
represents methylated cytosine 
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Figure 2.2 Interpretation of sequencing results 
Sequencing results of two clones from the same sample are shown. The CpG being 
studied is circled in red. The CpG at the top was unmethylated as a thymine was 
revealed at the original position of the cytosine. The CpG at the bottom was 






3.1 Work flow 
This was a cross-sectional study aimed at comparing the methylation 
patterns of the 16 CpG sites within the LCR of HPV 16 genome harboured in 
invasive cervical cancer and low-grade lesions. Methylation patterns of CaSki 
and SiHa cells were also analyzed. The work flow of the study is summarized 
in Figure 3.1. 
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Sequencing of clones 
Figure 3.1 Work flow 
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3.2 Study subjects 
Two groups of patients and two cervical cancer cell lines CaSki and 
SiHa (ATCC, USA) were included in this study. All clinical samples were 
archival and had HPV 16 as the only HPV type detected. 
3.2.1 Invasive cervical cancer group 
Cancer group consisted of biopsy samples with histological diagnosis of 
invasive cervical squamous cell carcinoma (SCC). The samples had been 
collected during the course of previous studies with a written informed consent. 
The patients were Chinese women who were referred to the colposcopy clinic 
at The Prince of Wales Hospital for further management following abnormal 
results. 
3.2.2 Low-grade group 
Low-grade group consisted of cervical cytology samples with 
pathology of CIN 1 or normal. Subjects were classified as being normal if the 
results of follow-up cytology after at least six months were normal. The 
samples had been collected during the course of previous studies with a written 
informed consent. Majority of the samples were cervical exfoliated cells 
collected from Chinese women who were referred to the colposcopy clinic at 
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The Queen Elizabeth Hospital or The Prince of Wales Hospital for further 
management following abnormal cytological results. The remaining samples 
were cervical scrape samples collected from women enrolled for cervical 
screening at a community based clinic in Macao. 
3.2.3 Cell lines 
Cervical cancer cell lines CaSki and SiHa (ATCC, USA) contained one 
single copy and around 600 copies of integrated HPV 16 genome per cell, 
respectively. Stock of frozen cell pellets of the two cell lines was used for DNA 
extraction. 
3.3 DNA extraction 
Extracted DNA preparations of cancer samples had been prepared 
during the course of previous studies. DNA extraction of low-grade samples 
and the two cell lines were done by QIAamp DNA Mini Kit (QIAGEN, 
Germany). Following the manufacturer's protocol, 20 fxL of QIAGEN Protease 
and 200 fxL of Buffer AL were added to 200 [iL of sample and incubated at 
56°C for 10 min. After incubation, 200 ^iL of ethanol were added and the 
mixture was applied to the QIAamp Spin Column and centrifuged at 6,000 x g 
for 1 min. The column was washed with 500 ^iL of AWl by centrifugation at 
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6,000 X g for 1 min and then with 500 ^iL of AW2 by centrifugation at 20,000 x 
g for 3 min. The QIAamp Spin Column was placed in a 1.5-mL 
microcentrifuge tube and 100 mL of distilled water were added. After 1-min 
incubation at room temperature, DNA was eluted by centrifugation at 6,000 x g 
for 1 min. DNA was stored at -70�C for later use. 
3.4 HPV genotyping 
HPV genotyping of the clinical samples had been done in the course of 
previous studies by reverse line-blot hybridization using the LINEAR ARRAY 
HPV Genotyping Kit (Roche Molecular Systems, Inc., USA). The primer mix 
� contained biotinylated primers which amplified the LI gene fragment of around 
450 bp of 37 different HPV genotypes. The amplicons were denatured and 
hybridized on the genotyping strips. Streptavidin-horseradish peroxidase 
conjugate was added to the amplicons and blue lines indicating the presence of 
different HPV types were resulted after adding the substrate solution. 
3.5 PCR ofHPV16 LCR 
PCR for HPV 16 LCR was performed to assess the quality and quantity 
of the extracted DNA. PCR products were also sequenced to look for mutations. 
PCR was performed in a 50-^iL reaction mixture containing Tris-HCL, KCL, 
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(NH4)2S04，1.5 mM of MgCb, 1.25 units of HotStarTaq DNA polymerase 
(QIAGEN, Germany), 200 \iM of each DNTP (GE Healthcare, UK) and 0.1 
|iM of each primer (Table 2.1). Five microlitres of extracted DNA were used as 
template. The PGR cycling conditions included an initial denaturation and 
enzyme activation at 95°C for 5 min, followed by 40 cycles of 1-min 
denaturation at 94°C, 1-min annealing at 58°C and 1-min extension at 72°C. A 
final extension was carried out at 12°C for 8 min. Ten microlitres of each PGR 
product were subjected to gel electrophoresis by running a 2% agarose gel at 
120 volts for 1 hr. The PGR products with expected band size of 1000 bp were 












































































































3.6 Sequencing of HPV16 LCR 
3.6.1 Purification of PCR products 
The PCR products of HPV 16 LCR were purified by Microspin S-400 
(GE Healthcare, UK) prior to sequencing. The resin in the spin column was 
resuspended by vortexing and spinning at 735 x g for 1 min. PCR products 
were added to each of the column and centrifuged at 735 x g for 2 min. Purified 
products were collected in 1.5-mL microcentrifuge tubes. 
3.6.2 Cycle sequencing reaction 
Cycle sequencing reaction was performed using the ABI Prism BigDye 
Terminator v. 3.1 Cycle Sequencing Kit (Applied Biosystems, USA). The 
sequencing reaction was performed in a 10-[xL mixture containing 1 |xL of 
BDT ready reaction mix, 1.5 |xL of BigDye sequencing buffer, and 1.6 pmol of 
LCR forward primer (Table 3.1). Five microlitres of purified PCR products 
were added as template. The reaction included an initial denaturation at 96°C 
for 1 min, followed by 25 cycles of 10-sec denaturation at 96°C, 5-sec 
annealing at 50°C and 1 min 15 sec of extension at 60 °C. 
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3.6.3 Purification of cycle sequencing products 
Cycle sequencing products were purified by DyeEx 2.0 Spin Kit 
(QIAGEN, Germany). The resin in the spin column was resuspended by 
vortexing and spinning at 750 x g for 3 min. PGR products were added to each 
of the column and centrifuged for another 3 min. Purified products were 
collected in 1.5-mL microcentrifuge tubes. 
3.6.4 Sequencer and data analysis 
Three microlites of each purified cycle sequencing product were added 
to 9 |iL of Hi-Di formamide (Applied Biosystems, USA) on a 96-well 
microtitre plate. The plate was then heated at 95°C for 2 min and then 
transferred to an ice block. The samples were injected into the ABI Prism 3130 
Genetic Analyzer for sequencing (Applied Biosystems, USA). ABI PRISM 
Seqcape software v. 2.5 was used for sequence analysis. HPV16R was used as 
a reference sequence. 
3.7 Bisulfite modification 
Samples with the LCR successfully amplified were selected for bisulfite 
modification. Extracted DNA was bisulfite modified using the EZ DNA 
Methylation-Gold Kit (Zymo Research, USA). 
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The CT Conversion Reagent supplied in the kit was a solid mixture and 
was designed for 10 separate DNA modifications per tube. Each tube of reagent 
was prepared by incubating with 600 [aL of water, 300 [xL of M-Dilution Buffer 
and 50 \iL of M-Dissolving Buffer at room temperature with shaking for 10 
min. After incubation, 100-fxL aliquots of the reagent were stored in separate 
microcentrifuge tubes. Twenty to fifty microlitres of DNA sample were added 
in each reaction with the addition of distilled water to compensate the 
difference. Incubation of 98°C for 10 min and 64�C for 2.5 hr was performed. 
Each reaction was then mixed with 600 \iL of M-Binding Buffer in a Zymo-
Spin IC Column and centrifuged at 20,000 x g for 30 sec. The column was 
washed with 100 fxL of M-Wash buffer by centrifugation at 20,000 x g for 30 
sec. The column was then incubated together with 200 (xL of M-
Desulphonation at room temperature for 15 - 20 min and centrifuged at 20,000 
X g for 30 sec. It was then placed into a 1.5-mL microcentrifuge tube and 10 ^iL 
of distilled water was added. The modified DNA was eluted after 1-min 
incubation at room temperature. A second elution was done with another 10 ^iL 
of distilled water. The modified DNA was stored at -70�C for later use. 
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3.8 PCR of bisulfite modified LCR 
The LCR after bisulfite modification was amplified in two amplicons 
(Al and A2). The LCR was too long to be amplified in one single reaction due 
to random fragmentation of the bisulfite modified DNA. The two amplicons 
were amplified by Al primers and A2-(l) primers, respectively (Table 3.2). If 
no visible band or a weak band was observed after the first round of Al PCR, 
second round of PCR was performed using the Al primers again. If no visible 
band or a weak band was observed after the first round of A2 PCR, PCR was 
repeated using A2-(2) primers in the first round of PCR and A2-(l) in the 
second round of PCR (Table 3.2). 
PCR was performed in a 50-[a,L reaction mixture containing Tris-HCL, 
KCL, (NH4)2S04，3 mM of MgC^, 1.25 units of HotStarTaq DNA polymerase 
(QIAGEN, Germany), 100 ^iM of each DNTP (GE Healthcare, UK) and 0.1 
^iM of each primer (Table 3.2). Five microlitres of modified DNA were used as 
template in the first round of PCR and 5 (iL of the first-round PCR products 
were used as template in the second round of PCR. The PCR cycling conditions 
included an initial denaturation and enzyme activation at 95°C for 5 min, 
followed by 40 cycles of 1-min denaturation at 94°C, 1-min annealing at 55°C 
and 1-min extension at 12°C. A final extension was carried out at 72°C for 8 
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min. Ten microlitres of each PCR product were subjected to gel electrophoresis 
by running a 2% agarose gel at 120 volts for 1 hr. The products with expected 

















































































































































































































































































































Samples that had both Al and A2 successfully amplified were selected 
for cloning. The PCR products were first purified by Microspin S-400 (GE 
Healthcare, UK). Ligation was performed in a 10-fxL reaction consisted of 1 |iL 
of lOX Ligation Buffer, 50 ng of pCR 2.1 vector and 4 units of T4 DNA Ligase. ‘ 
The ligation buffer was composed of 6 mM of Tris-HCl, 6 mM of MgCl2, 5 
mM of NaCl, 7 mM of P-mercaptoethanol, 0.1 mM of ATP, 2 mM of 
dithiothreitol, 1 mM of spermidine and 2 mg/ml of bovine serum albumin. Six 
microlitres of purified PCR products were added in each reaction. The ligation 
reaction was incubated at 14°C overnight. 
3.9.2 Transformation 
Five microlitres of each ligation reaction were added to 50 fxL of 
TOP 10 competent cells (Invitrogen, USA) and incubated on ice for 30 min. The 
mixture was heat shocked for 30 sec at 42�C and immediately transferred back 
to ice. Each tube was then incubated with 250 [xL of Super Optimal Broth 
(S.O.C.) medium at 37�C for 1 hr with shaking. All the content of each tube 
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was then spread on pre-warmed Luria-Bertani (LB) agar plates containing 100 
fxg/ml of ampicillin and incubated at 37�C overnight. 
3.9.3 Colony PCR 
Colonies formed on each transformation plate were screened by colony 
PCR until at least 15 positive clones were obtained. Colony PCR was 
performed in a 25-jxL reaction mixture containing Tris-HCL, KCL, (NH4)2S04, 
0.75 mM of MgCl2, 0.625 units of HotStarTaq DNA polymerase (QIAGEN, 
Germany), 100 ^iM of each DNTP (GE Healthcare, UK) and 0.1 \iM of each 
primer. Colonies were picked with pipette tips and dipped in the reaction 
mixture. Five microlitres of each PCR product were subjected to gel 
electrophoresis by running a 2% agarose gel at 120 volts for 1 hr. Al clones 
with a band size of 713 bp and A2 clones with a band size of 648 bp were then 
sequenced. 
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Table 3.3 M-13 primer sequences of colony PCR 
Primer Sequence Amplicon size (bp) 
M-13 Al :713, A2:648 
Forward 5-‘GTA AAA CGA CGG CCA G-3' 
Reverse 5’-CAG GAA ACA GCT ATG AC -3' 
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3.10 Sequencing of clones 
3.10.1 Purification of PGR products 
The colony PGR products were purified by Microspin S-400 (GE 
Healthcare, UK) prior to sequencing. The resin in the spin column was 
resuspended by vortexing and spinning at 735 x g for 1 min. PGR products were 
added to each of the column and centrifuged at 735 x g for 2 min. Purified 
products were collected in 1.5-mL microcentrifuge tubes. 
3.10.2 Cycle sequencing reaction 
Cycle sequencing reactions were performed using the ABI Prism BigDye 
Terminator v. 3.1 Cycle Sequencing Kit (Applied Biosystems, USA). The 
sequencing reaction was performed in a 10-|iL mixture containing 1 \iL of BDT 
ready reaction mix, 1.5 of [jiL BigDye sequencing buffer and 1.6 pmol of M-13 
forward primer (Table 3.3). Two microlitres of template were added as template. 
Reaction included an initial denaturation at 96�C for 1 min, followed by 25 
cycles of 10-sec denaturation at 96°C, 5-sec annealing at 50�C and 1 min 15 sec 
of extension at 60°C. 
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3.10.3 Purification of cycle sequencing products 
Cycle sequencing products were purified by DyeEx 2.0 Spin Kit 
(QIAGEN, Germany). The resin in the spin column was resuspended by 
vortexing and spinning at 750 x g for 3 min. PCR products were added to each 
column and centrifuged for another 3 min. Purified products were collected in 
1.5-mL microcentrifuge tubes. 
3.10.4 Sequencer and data analysis 
Three microlites of each purified cycle sequencing product were added to 
9 \xL of Hi-Di formamide (Applied Biosystems, USA) on a 96-well microtitre 
plate. The plate was then heated at 95�C for 2 min and then transferred to an ice 
block. The samples were injected into the ABI Prism 3130 Genetic Analyzer 
(Applied Biosystems, USA) for sequencing. ABI PRISM Seqcape software v. 
2.5 was used for sequence analysis (Applied Biosystems, USA). HPV16R was 
used as a reference sequence. 
3.11 Statistical methods 
Statistical analysis of the methylation frequency of each CpG site of the 
cancer samples and its comparison with the methylation frequency of the low-
52 
grade samples was done by Prism 5 for Windows Version 5.04 (GraphPad 
software Inc., USA). The difference of methylation frequency of each CpG site 
between the cancer samples and the low-grade samples was tested by Mann-
Whitney test. The comparison of methylation frequency and location of 
methylation between the cancer samples and the low-grade samples was 
examined by Chi-squared test or Fisher's exact test using Epi Info Version 6.0 





4.1 Sample selection 
Cervical samples with single HPV 16 infection taken from patients with 
the appropriate pathological diagnosis were chosen and subjected to LCR PCR, 
bisulfite modification, Al and A2 PCR, cloning and sequencing. Samples failed 
at each stage were excluded in the subsequent procedures. The selection process 
continued until the results of at least 20 cancer samples and 20 low-grade 
samples were obtained. Eventually, 23 cancer samples and 20 low-grade samples 
were included in this study. The lower successful rate of low-grade samples than 
cancer samples at each stage was due to the weaker DNA quantity and quality of 
� low-grade cervical scrapes than cancer biopsies. 
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Cancer samples Low-grade samples 
27 HPV 16 LCR PGR 48 
27 Bisulfite modification 35 
» « 
人 , 
27 Al andA2 PGR .35 
27 Cloning 20 
- » 
23 Sequencing 20 
Figure 4.1 Number of samples attempted at each stage 
The number of samples attempted at each stage is shown. A total of 23 cancer 
samples and 20 low-grade samples were included in this study. 
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4.2 HPV16 LCR PCR and sequencing 
PCR of HPV 16 LCR before bisulfite modification was carried out to 
assess the DNA quality and the PCR products were sequenced to look for 
nucleotide variations. HPV16R was used as a reference sequence in this study. A 
total of 15 nucleotide variations were identified in the 850 bp of LCR (Appendix 
I). The number of nucleotide variations found in individual samples ranged from 
zero to 11. Six nucleotide variations were detected in CaSki cell line and three in 
SiHa cell line. Only two cancer samples (WBX 1258 and WBX 1660) and one 
low-grade sample (QE 516) had identical LCR sequences as that of HPV16R. 
One of the nucleotide variations was found at the CpG site at position 
7270. 7270C > T was detected in 18 of the 23 (78.3%) cancer samples and 12 of 
the 20 (60.0%) low-grade samples. Therefore, the CpG site at position 7270 was 
in fact absent in majority of the samples. No mutation of the other 15 CpG sites 
was detected in the samples and all 16 CpG sites were present in CaSki and SiHa 
cell lines. 
Twelve of the 23 (52.2%) cancer samples and nine of the 20 (45.0%) 
low-grade samples contained the same 11 nucleotide variations. On the other 
hand, 7393T > A and 7394C > T variations detected in CaSki cell line were not 
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found in any samples, whereas both 73 IOC > G and 12T > C variations were 
only detected in CaSki cell line and one cancer sample (WBX 366). Nucleotide 
variation of 7287A > C was found in 27 of the 40 samples (67.5%) and 7287A > 
T was observed in one cancer sample (WBX 666). Similarly, 7289A > C was 
found in 22 of the 40 samples (55.0%) and 7289A > T was noticed in only one 
cancer sample (WBX 1604) and one low-grade sample (QE 188). 
58 
7267 A 7277 
T A A T A A A C A C G T G T G T A T G Reference sequence 
T A A T A A A C A C G T G T G T A T G 
W W l H / l M k i W W W No mutation at position 7270 
T A A T A A A C A T G T G T G T A T G 
驢 kAkM c>——p—— 
Figure 4.2 Sequencing result of C > T mutation at nucleotide position 7270 
Sequencing results of two samples are shown. The sequence at the top had no 
mutation at position 7270 (circled in red). The sequence at the bottom had 
7270C > T mutation, which was found in 78.3% of cancer samples and 60.0% of 
low-grade samples. 
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_ _ _ 
Figure 4.3 Agarose gel electrophoresis of HPV 16 LCR PGR products 
？hill4-HaeIII was used as a molecular marker. Lanes 1 - 10 show products of 
HPV 16 LCR PGR. The expected product size is 1000 bp. 
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4.3 Methylation patterns 
Bisulfite sequencing was the method used to study methylation pattern in 
this study. Bisulfite modification alters cytosines to uracils through deamination. 
Methylated cytosines are however protected from this modification. 
Unmethylated cytosines will appear as thymines after sequencing and 
methylated cytosines will remain unchanged. 
4.3.1 Cell lines 
The LCR methylation patterns of the HPV 16 genomes harboured in the 
two cervical cancer cell lines, CaSki and SiHa, were studied. Fifteen clones of 
both Al and A2 of SiHa were sequenced. However, only nine Al and 11 A2 
sequences of CaSki were obtained due to difficulties in cloning. Methylation was 
extensive in CaSki but rare in SiHa (Table 4.1). All of the 16 CpG sites were 









































































































































































































































































































































































4.3.2 Cancer group 
4.3.2.1 Overview 
The cancer group consisted of 23 cervical squamous cell carcinoma 
samples. Single round of PCR was adequate for amplification of both amplicons 
of all samples. Fifteen to 20 clones of each amplicon were sequenced per sample, 
with an average number of 17 clones. The number of clones sequenced for each 
sample is shown in Table 4.2. 
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Al A 2 
513 b p — — ^ — — 4 4 8 bp 
* � 
Figure 4.4 Agarose gel electrophoresis of A l and A2 PCR products of the 
cancer samples 
1 kb Plus was used as a molecular marker. Lanes 1 - 3 show Al PCR products 
with expected product size of 513 bp. Lanes 4 - 5 show A2 PCR products with 
expected product size of 448 bp. 
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Table 4.2 Number of Al and A2 clones sequenced for each cancer sample 
Cancer samples No. of Al clones No. of A2 clones 
WBX 342 19 15 
WBX 366 17 16 
WBX 492 16 15 
WBX 530 18 20 
WBX 630 20 20 
WBX 665 20 17 
WBX 666 15 18 
WBX 692 19 15 
WBX 755 20 18 
WBX 922 18 15 
WBX 991 17 17 
WBX 1114 15 15 
WBX 1120 16 16 
WBX 1143 16 18 
WBX 1149 18 15 
WBX 1258 18 18 
WBX 1570 20 18 
WBX 1579 17 16 
WBX 1604 19 15 
� WBX 1605 18 16 
WBX 1606 15 15 
WBX 1607 16 16 
WBX 1660 16 
65 
4.3.2.2 Methylation pattern of the cancer samples 
Out of the 23 cancer samples, 20 (87.0%) contained one or more 
methylated CpG sites (me-CpGs) within the LCR. Figure 4.5 shows the number 
of cancer samples with the respective number of me-CpGs. The number of me-
CpGs in each sample ranged from zero to all 16 CpG sites, with a median of four 
me-CpGs. The cancer samples were arbitrarily divided into three groups based 
on the number of me-CpGs. The "low-level methylation group" defined as 
having zero to five me-CpGs comprised 13 samples. The "medium-level 
methylation group" defined as having six to 10 me-CpGs contained six samples 
� and the "high-level methylation group" defined as having 11 to 16 me-CpGs 
contained four samples. 
Table 4.3 shows the percentage of clones of each cancer sample that had 
methylation at each CpG site. Due to the mutation of 7270C > T, the CpG site at 
position 7270 was lost in 18 of the 23 (78.3%) cancer samples. Three of the five 
samples (60.0%) that contained the CpG site at position 7270 had methylation 
detected at this site. Figure 4.6 shows box plots of methylation frequency at each 
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Figpre 4.5 Number of methyJatedl CpG sites in the cancer samples 
Number of cancer samples that had the respective number of methylated CpG 
sites (me-CpGs) is shown. The cancer samples were categorized in to three 
groups according to the number of me-CpGs detected: 
Low-level methylation group: 0 - 5 me-CpGs 
Medium-level methylation group: 6 - 1 0 me-CpGs 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. Cancer group (all subjects) 
Promoter region 
5' LCR I ^ ^ 
c 彻 1 j Enhancer region 了 t nr t 
•2 90- A , 丁 
I 7� - I \ 
I 60- T T Silencer 
0 50- 丁 丁 人 
a 40- T T 丁 ^ C I 
1 30- T T T X 
o 20- p i JL r-H 
左 i r f i r}i i t i 171 rfi n rfi rfi 丨•丨 I7I 丨 J 丨 J 丨 , -
7428 7434 7455 7461 7636 7653 7676 7682 7694 7862 31 37 43 52 68 
Nucleotide position of CpG sites 
Figure 4.6A Box plot of methylation frequency of each CpG site in the 
cancer group (all subjects) 
The limits, lower quartile, median and upper quartile of the methylation 
frequency of each CpG site are shown. The data in Table 4.3 was used to plot the 
graph. 
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B. Cancer group (low-level methylation) 
5' LCR 
Promoter region 
30n/ * \ , i , 
o Enhancer region ( \ 
^ 25- 丁 丁 Ji T 
^ 20- T T T 
E 
0 1S- Silencer 
1 10- A 
I 5- T J T T T T 
左 olnncir；] I I . . M I M I I 
7428 74347455 74617536 7663 7676 7682 7694 7862 31 37 43 52 58 
Nucleotide position of CpG sites 
Figure 4.6B Box plot of methylation frequency of each CpG site in the 
cancer group (low-level methylation). • 
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C. Cancer group (medium-level methylation) 
Promoter region 
40-1 K 
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7428 743474557461753575537676768276947862 31 37 43 52 58 
Nucleotide position of CpG sites 
Figure 4.6C Box plot of methylation frequency of each CpG site in the 
cancer group (medium-level methylation). ( 
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D. Cancer group (high-level methylation) 
Promoter region 
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Nucleotide position of CpG sites 
Figure 4.6D Box plot of methylation frequency of each CpG site in the 
caecer group (high-level methylation). 
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4.3.2.3 Methylation pattern of the promoter region 
The five CpG sites within the promoter region were located within one 
SPl binding site and two E2 binding sites (E2BS3 and E2BS4). Fourteen of the 
23 samples (60.9%) contained methylation of one or more of the five CpG sites 
within the promoter region. It was noted that 90% of clones that had methylation 
of one of the two CpG sites within an E2BS had the second CpG site methylated 
as well. Furthermore, nine of the 14 samples (64.3%) that had any methylation 
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Figure 4.7 Methylation pattern of the CpG sites within the promoter region 
in the cancer samples 
The five CpG sites within the promoter region were located within one SPl 
binding site and two E2 binding sites (E2BS3 and E2BS4). Fourteen samples 
had methylation of one or more CpG sites within the promoter region and nine 
of them had all five CpG sites methylated together. 
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4.3.3 Low-grade group 
4.3.3.1 Overview 
The low-grade group comprised 20 cervical cytology samples taken from 
nine subjects with normal cervix and 11 subjects with CIN 1 confirmed by 
histology. Two rounds of PCR of both Al and A2 were performed for all 
samples in order to obtain sufficient PCR products for sequencing. Fifteen 
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Figure 4.8 Agarose gel electrophoresis of A2 first-round PCR products of 
low-grade samples 
( 
Phil74-//flg/// was used as a molecular marker. Lanes 1 - 4 show products of A2 
first-round PCR products. The expected product size is 713 bp. 
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^ j m ^ u ^ j — • bp 
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Figure 4.9 Agarose gel electrophoresis of A2 second-round PCR products of 
low-grade samples 
WillA-Haelll was used as a molecular marker. Lanes 1 - 4 show A2 second-
round PCR products of the four samples shown in Figure 4.7. The expected 
product size is 448 bp. Band intensities were enhanced when compared with the 
first-round PCR products. 
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4.3.3.2 Methylation pattern of the low-grade samples 
Twelve of the 20 samples (60.0%) contained one or more methylated 
CpG sites (me-CpGs) within the LCR. Figure 4.10 shows the number of low-
grade samples with the respective number of me-CpGs. The number of me-CpGs 
of each sample ranged from zero to three, with a median of one me-CpG. Figure 
4.11 shows the number of low-grade samples that had methylation at each of the 
CpG site. Eight of the 16 (50.0%) CpG sites were methylated in the low-grade 
group. The CpG site at position 7428 was methylated in five of the 12 samples 
(41.7%) that had any methylation within LCR. 
� Table 4.4 shows the percentage of clones of each low-grade sample 
containing methylation at each CpG site. Due to the mutation of 7270C > T, the 
CpG site at position 7270 was lost in 12 of the 20 (60.0%) low-grade samples. 
None of the eight samples that contained the CpG site at position 7270 had 
methylation detected at this site. The average methylation frequency was the 
highest in the CpG site at position 7428 (5.7%), followed by the CpG site at 
position 52 (5.3%), positions 7434 and 7535 (5.0% each), position 7553 (1.7%) 
and positions 7676，7694 and 7862 (0.3% each). However, 15 of the 16 clones 
79 . 
that had methylation at the CpG site at position 52 were originated from the 
same sample (QE 946). 
t 
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Figure 4.10 Number of methylated CpG sites in the low-grade samples 
Number of low-grade samples that had the respective number of methylated 
CpG sites is shown. A maximum number of three me-CpGs was found in 
individual samples. 
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4.3.4 Comparison of the methylation patterns of the cancer samples and the 
low-grade samples 
Methylation was detected in 87.0% of the cancer samples and 60.0% of 
the low-grade samples. Methylation of all CpG sites present within LCR was 
found in four cancer samples whereas the maximum number of me-CpGs 
detected in individual low-grade samples was three. The median of number of 
me-CpGs in the cancer samples was four in contrast to median of one me-CpG 
in the low-grade samples. Table 4.5 compared the methylation frequency of the 
cancer group and the cancer subgroups with the low-grade group. The number of 
� samples with methylation was significantly higher in the cancer group when 
compared to the low-grade group. 
The five CpG sites within the promoter region were highly methylated in 
the cancer group. One or more me-CpGs within the promoter region were 
detected in 14 of the 23 (60.9%) cancer samples. Nine cancer samples (39.1%) 
even had all five CpGs within the promoter region methylated. In contrast, only 
the CpG site at position 52 within the promoter region was found to be 
methylated in two of the 20 (10.0%) low-grade samples. Location of methylation 
in the cancer group and its subgroups was compared with the low-grade group 
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(Table 4.6). The methylation frequency of the promoter region in the cancer 
group and also the medium-level and the high-level methylation subgroups was 
significantly higher when compared to the low-grade group. Methylation 
frequency of the 5’ LCR and the silencer region were significantly increased in 
the cancer group and the high-level methylation subgroup, respectively. The 
difference in methylation frequency in the enhancer region was not significant 
between the cancer samples and the low-grade samples. 
Figure 4.12 compared the methylation frequency of each CpG site of the 
cancer group and its subgroups with the low-grade group by Mann-Whitney test. 
� The CpG site at position 7270 was excluded due to its absence in majority of the 
samples. Methylation frequency of 10 CpG sites was found to be significantly 
increased in the cancer group. Two, seven and all 15 CpG sites were more 
frequently methylated in the low-level, medium-level and high-level methylation 
subgroups, respectively compared to the low-grade group. All five CpG sites in 
the promoter region had significantly increased methylation frequency in the 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. Cancer group (all subjects) vs. low-grade group 
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Figure 4.12A Comparison of methylation frequency of each CpG site in the 
cancer group (all subjects) and the low-grade group 
The mean of methylation frequency of each CpG site in the cancer group (all 
subjects) and the low-grade group was compared. The error bars represent 
standard error of the mean. The CpG sites with methylation frequency 
significantly increased in the cancer samples (Mann-Whitney test, P < 0.05) are 
marked with asterisks. 
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B. Cancer group (low-level methylation) vs. low-grade group 
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Figure 4.12B Comparison of methylation frequency of each CpG site in the 
cancer group (low-level methylation) and the low-grade group 
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C. Cancer group (medium-level methylation) vs. low-grade group 
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Figure 4.12C Comparison of methylation frequency of each CpG site in the 
cancer group (medium-level methylation) and the low-grade group 
* 
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D. Cancer group (high-level methylation) vs. low-grade group 
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Figure 4.12D Comparison of methylation frequency of each CpG site in the 






The aim of this study is to characterize the methylation pattern of the 16 
CpG sites within HPV 16 LCR and to delineate its potential to be a novel marker 
of cervical cancer. The reason of studying HPV viral gene methylation is 
because methylation appears to have roles in the regulation of viral gene 
transcription and could be an alternative mechanism other than viral integration 
in driving carcinogenesis. 
The promoter region in the 3，LCR, the enhancer region in. the central 
LCR and the 5' LCR each contains five CpG sites whereas the silencer region 
contains one CpG site. Twelve of the 16 CpG sites are situated within cellular 
transcription factor binding sites and the four E2 binding sites (E2BSs). E2BS1 
situates in 5，LCR, E2BS2 in the silencer region and E2BS3 and E2BS4 in the 
promoter region. The functions of E2 in regulation of transcription and 
replication rely on its ability to bind to the four E2BSs within LCR and the 
importance of E2BSs is reflected by their highly conserved structure. ( 
5.1 Sequence variations of HPV16 LCR 
The LCR of HPV 16 genomes harboured in samples as well as CaSki and 
SiHa cell lines was sequenced. The HPV16R was used as reference sequence 
(Myers et al., 1995). HPV16R is a revised sequence with correction of the 
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sequencing errors contained in the originally published HPV 16 sequence 
(Seedorf et al., 1985). HPV16R was used as a reference for the nucleotide 
position numbering of the CpG sites as it contains all the 16 CpG sites in the 
LCR targeted in this current study. HPV16R is also a commonly used reference 
sequence in previous studies (Badal et al., 2003; Meissner, 1999). 
Sequence variation of 7270C > T was found in 18 of the 23 (78.3%) 
cancer samples and 12 of the 20 (60.0%) low-grade samples but not in CaSki 
and SiHa cell lines. This nucleotide variation was not reported in previous 
HPV 16 LCR methylation studies (Badal et al., 2003; Brandsma et al., 2009; 
Ding et al., 2009; Kalantari et al., 2004; Rajeevan et al., 2006). However, this 
CpG site was not included in one of these studies but the reason was not stated 
(Ding et al., 2009). Nucleotide variation of C > T at a CpG site mimics the 
sequencing result of an unmethylated CpG. Therefore, the nucleotide variation 
of 7270C > T would not be noticed and would be misinterpreted as an 
unmethylated CpG if sequencing of LCR of the original sample was not done. 
This nucleotide variation can be the reason of no or little methylation of this 
CpG reported in previous studies (Brandsma et al., 2009; Kalantari et al., 2004). 
The study done by Kalantari et al. reported minimal methylation of the CpG at 
position 7270 in all three patient groups of asymptomatic infection, CIN lesion 
97 . 
and cervical cancer. It is worthwhile to investigate whether Kalantari's findings 
reflect the common lost of CpG site at position 7270 as observed in our study. 
5.2 Methylation patterns of CaSki and SiHa cell lines 
In the current study, extensive methylation of the LCR was detected in 
the HPV 16 genomes harboured in CaSki. Methylation of all 16 CpG sites was 
detected in CaSki. Percentage of clones with methylation at individual CpG sites 
ranged from 11.1% to 100%. The four CpG sites at positions 31, 43，52 and 58 
had methylation in all of the clones sequenced. In another words, four of the five 
CpG sites within the promoter region had 100% methylation. On the other hand, 
only two CpG sites were methylated at low frequency (6.7% and 13.3%) in the 
HPV 16 genomes harboured in SiHa. Similar results of the large difference in 
methylation levels between the two cell lines have been reported previously 
(Badal et al., 2003; Rajeevan et al., 2006). Large difference in methylation 
frequency of the two cervical cancer cell lines was also seen in the cancer 
samples of this study. This could be due to different mechanisms were being 
utilized in driving HPV carcinogenesis in the cancer samples. 
98 
5.3 Methylation pattern of the cancer samples 
The 23 cancer samples were arbitrarily divided into three groups 
according to the number of methylated CpG sites (me-CpGs) detected. 
Methylation was hypothesized to be one of the mechanisms involved in HPV 
carcinogenesis. If sub-grouping was not done, the methylation pattern of the 
samples in which methylation was being utilized in carcinogenesis would be 
masked. 
The methylation patterns were found to be distinct in the three cancer 
subgroups. The low-level methylation subgroup being defined as samples with 
zero to five me-CpGs showed preferential methylation at the 5’ LCR. However, 
methylation of the 5’ LCR has no identified roles in cancer progression. 
The medium-level methylation subgroup defined as having six to 10 me-
CpGs showed highest methylation frequency of the CpG sites within the 
promoter region. Five of the six samples in this group even had methylation of 
all of the five CpGs sites in the promoter, region. Methylation of the promoter 
region abolishes E2-mediated repression and hence E6 and E7 oncogene 
expression will be enhanced. Therefore, methylation of the promoter region 
should be beneficial to cancer progression. 
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The remaining four samples, which had all of the CpG sites present in the 
LCR methylated, were categorized in the high-level methylation subgroup. 
Methylation frequency at individual CpG sites had a wide range of 2.7% to 
93.8%. The promoter region was again the most frequently methylated region. 
Similar to the medium-level methylation subgroup, methylation of the promoter 
region could be a mechanism in driving HPV carcinogenesis. 
The especially high methylation frequency of the promoter region is not 
as obvious in the cancer group as in the medium-level and high-level 
methylation subgroups. Therefore, subgroup analysis is important in revealing 
the methylation pattern that can represent cancer progression. This approach was 
not used in previous HPV methylation studies and might lead to 
misinterpretation of results. 
5.4 Methylation pattern of the low-grade samples 
Only 12 of the 20 (60%) low-grade samples had any me-CpGs and the 
methylation frequency was generally low. Methylation was most frequent in the 
5’ LCR and lowest in the promoter region, in contrast to the highest methylation 
frequency in the promoter region in the cancer samples. Only the CpG site at 
position 52 in the promoter region was methylated. However, 15 of the 16 clones 
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with methylation at position 52 came from the same sample, QE 946, which 
harboured CIN 1 lesion. In fact, all of the clones of QE 946 sequenced contained 
methylation at position 52. Unmethylated CpG can be mimicked by C > T 
mutation but CpG will not be falsely interpreted as methylated because of 
mutations. Therefore, it is intriguing to have 100% methylation of a CpG site in 
a sample of the low-grade group, in which methylation was generally rare. It will 
be interesting to have follow-ups of the patient from whom QE 946 was taken -
from to see if the HPV infection has further progressed. The data however is not 
available. 
5.5 Comparison of methylation patterns of the cancer samples and the low-
grade samples 
Methylation in general represses transcription due to blockage of 
transcription factors binding. However, methylation does not affect binding of 
all transcription factors. For example, the binding of the cellular transcription 
factors SPl and YYl is not affected by methylation of their binding sites 
(Gaston and Fried, 1995; Holler et al., 1988). Therefore, the effect of 
methylation has to be interpreted by looking at individual sites where 
methylation occurs. 
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5.5.1 Promoter region in 3，LCR 
The promoter region contains five CpGs sites, which are situated within 
one SPl binding site and two E2BSs (E2BS3 and E2BS4). These CpG sites are 
just proximal to p97, the early promoter of HPV 16, which controls the 
transcription of HPV 16 oncogenes E6 and E7. Methylation of the promoter 
region was more frequent in the cancer group, the medium-level and high-level 
methylation subgroups when compared to the low-grade group. Moreover, a 
significant increase in methylation frequency of all of the five CpG sites within 
the promoter was also observed in the cancer samples. This elevated methylation 
of the promoter region in cancer samples when compared to asymptomatic 
samples has been reported previously (Bhattacharjee and Sengupta, 2006a; 
Kalantari et al., 2004). 
5.5.1.1 SPl binding site 
The CpG site at position 31 is contained within an SPl binding site. SPl 
is an activator of p97 (Stunkel and Bernard, 1999). The methylation frequency of 
this CpG site was significantly increased in the cancer group, the medium-level 
and high-level methylation subgroups when compared to the low-grade group. 
However, it has been shown that SPl binding is not affected by methylation of 
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its binding site (Holler et a l , 1988). Therefore, SPl can still bind and initiate 
transcription in the cancer samples with high methylation frequency of this site. 
Hence, methylation of this CpG site should not be involved in oncogenic 
progression. 
5.5.1.2 E2BS3 and E2BS4 
The CpG sites at positions 37 and 43 are located within E2BS3 and the 
CpG sites at positions 52 and 58 are situated within E2BS4. The methylation 
frequency of these four CpG sites was significantly increased in the cancer group, 
the medium-level and high-level methylation subgroups when compared to the 
low-grade group. The binding of E2 to E2BS3 displaces transcription activator 
SPl from its binding site (Tan et al., 1994) and E2 binding to E2BS4 occludes 
the binding of TATA-binding factor to TATA box. The binding of E2 to these 
two E2BSs therefore leads to transcription repression (Dostatni et al., 1991; Tan 
et al., 1992). Methylation of E2BSs has been shown to inhibit E2 bindingXThain 
et al., 1996). As a result of methylation of E2BS3 and E2BS4, SPl and TATA-
binding factor will not be displaced from their binding sites and transcription of 
E6 and E7 oncogenes could be initiated. Methylation of E2BS3 and E2BS4 can 
be one of the mechanisms leading to abolishment of E2-mediated repression. 
The effect will be similar to that of E2 disruption via viral integration or 
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mutations of E2 gene and E2BSs (Casas et a l , 1999; Giannoudis et al., 2001; 
Veress et a l , 1999). This should be beneficial to HPV carcinogenesis as 
sustained level of E6 and E7 expression is causally involved in transformation 
(Stoler, 2003). 
In the current study, it was noted that 90% of clones that had methylation 
at one of the CpG sites within an E2BS had the second CpG site within the same 
E2BS methylated at the same time. It has been shown that methylation of both of 
the CpG sites with an E2BS is required to cause complete abolition of E2 
binding (Thain et al., 1996). Furthermore, nine of the 23 cancer samples (39.1%) 
had all four CpG sites within E2BS3 and E2BS4 methylated. Therefore, binding 
of SPl and TATA-binding factor should not be affected even when E2 protein is 
in high concentration and hence transcription of E6 and E7 oncogenes will be 
sustained. This further supports the role of methylation of E2BS3 and E2BS4 in 
cancer progression. ‘ 
5.5.2 Silencer region 
The CpG site at position 7862 is located within the silencer region. 
Although this current study showed that methylation of this CpG site was more 
frequent in the high-level methylation cancer subgroup than in the low-grade 
group, methylation of this site was generally rare in all samples. Minimal 
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methylation frequency of this site has also been reported in previous HPV 16 
LCR methylation studies (Badal et al., 2003; Ding et al.，2009; Kalantari et al” 
2004; Rajeevan et al., 2006). A study of HPV 16 methylation of anal cancer 
samples reported that the CpG site at 7862 was the only site with no methylation 
detected among the 11 CpG sites within the enhancer and the promoter regions 
studied (Wiley et al., 2005). The CpG site at position 7862 is the only CpG site 
present in the silencer region of HPV 16 LCR. This CpG site is flanked by the ‘ 
silencer and the origin of replication. It is also contained within another E2BS 
(E2BS2). The binding of E2 to E2BS2 is involved in El-dependent replication 
through recruitment of E l DNA helicase to the replication of origin, proximal to 
E2BS2 (Yasugi et al., 1997). The lack of methylation of this CpG site in most 
samples might imply that the E2 function in recruiting El helicase to the origin 
of replication was maintained. Methylation of this CpG site should not be 
involved in oncogenic progression. 
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5.5.3 Enhancer region in central LCR 
The current study showed that the enhancer region was the region with 
the lowest methylation frequency in the cancer samples. Nonetheless, the 
increase in methylation frequency of CpG sites at 7676, 7682 and 7694 in the 
cancer group and the high-level methylation subgroup was still significant when 
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compared to the low-grade group. Kalantari's study also reported minimal 
methylation at positions 7535 and 7553 in all samples from patients with 
asymptomatic infection, CIN lesion or cervical cancer (Kalantari et al., 2004). 
The enhancer region contains five CpG sites. The CpG site at position 7553 is 
contained within a C/EBP binding site, the CpG sites at 7676 and 7682 within a 
PEF-1 binding site and the CpG site at 7694 within a TEF-1 binding site 
(Massimo Tommasino, 1997). C/EBP has been shown to repress HPV 16 
transcription (Akira et al., 1990) whereas PEF-1 and TEF-1 are activators of p97 
(Ishiji et al., 1992; Sibbet et al., 1995). HPV 16 p97 promoter only has moderate 
activity without the binding of transcription factors to the enhancer (Bernard, 
2002). The effect of methylation of these transcription factor binding sites to the 
binding of respective transcription factors has not been reported. Methylation at 
positions 7676, 7682 and 7694 within PEF-1 and TEF-1 binding sites was 
present in eight (34.8%)，five (21.7%) and seven (30.4%) cancer samples, 
respectively. This suggests that cancer development might not necessarily be 
inhibited by methylation of the binding sites of these transcription activators. 
5.5.4 CpG sites within 5，LCR 
The CpG sites at positions 7455 and 7461 had significantly higher 
methylation frequency in the cancer group when compared to the low-grade 
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group. Both of these sites were not methylated in any of the low-grade samples. 
These two CpG sites are situated within E2BS1, which has been proposed to 
have a role in mediating activation of HPV gene transcription (Kim et al., 2003). 
However, no promoters in genital HPV have been found to be strongly activated 
by E2 (Bernard, 2002). Methylation of E2BS1 should prevent the binding of E2. 
The consequence of inhibition of E2 binding to this E2BS is not certain. 
Nonetheless, this methylation should not prevent cancer progression as ‘ 
methylation of one or both of the CpG sites within E2BS1 was seen in 11 of the 
23 (47.8%) cancer samples of the current study. The other two CpG sites within 
the enhancer region at positions 7428 and 7434 had higher methylation 
frequency in the high-level methylation cancer subgroup than in the low-grade 
group. The effect of methylation of these sites could not be predicted as they are 
not situated within known transcription factor binding sites. 
5.6 Role of methylation in HPV16 
The role of methylation in HPV viral life cycle is not yet known. 
Methylation can be a host cell defence system, strategy of the virus to establish 
latent infection, mechanism involved in carcinogenesis or just an integral part of 
viral life cycle. In this study, the increase of methylation frequency of CpG sites 
in the cancer samples when compared to the low-grade samples was most 
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significant in the promoter region. Methylation of the promoter region inhibits 
E2 binding and abolishes E2-mediated repression of HPV gene transcription. 
This supports the role of methylation as an alternative mechanism to enhance E6 
and E7 oncogenes expression, which is believed to be a crucial event in HPV 
carcinogenesis. 
5.7 Potential as novel biomarker 
Novel and more robust biomarkers for cervical lesion progression are 
needed because cancer progression cannot be reliably predicted by Pap test or 
HPV DNA test. Methylation pattern has the potential of becoming a novel 
marker because it is found to be distinct in different cervical lesion grades. 
However, methylation was heterogeneous and no single CpG site was found to 
be completely methylated in the cancer samples. Nevertheless, this current study 
shows that the two E2 binding sites (E2BS3 and E2BS4) within the promoter 
region are the most potential targets to be developed into a marker as their 
methylation frequency was most significantly increased in the cancer samples 
when compared to the low-grade samples. Further studies can focus on these two 
E2BSs by employing high-throughput methods, such as methylation-specific 
PCR (MSP) or pyrosequencing, so that large number of samples can be analyzed 
in much shorter time. Furthermore, study of methylation of other regions of the 
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HPV genomes and different HPV types is also required to truly evaluate the 
potential of methylation pattern as marker in cancer detection. 
5.8 Conclusions 
This study once again demonstrated that HPV 16 genome is efficiently 
targeted by cellular methylation machinery. This raises questions of how HPV 
genomes are recognized by the cellular methylation enzymes and the roles of 
methylation in viral life cycle. The results of this current study conflict with that 
of some previous HPV 16 methylation studies (Badal et al., 2003; Brandsma et 
al., 2009; Kalantari et al., 2004), but agree with the results of Ding's study (Ding 
et al., 2009)，in which methylation frequency was found to be increased with the 
�• 
progression of cervical lesions. 
The hypothesis of distinct methylation patterns in different lesion grades 
was validated. Methylation of E2BS3 and E2BS4 was evident to have roles in 
HPV carcinogenesis. The potential of HPV DNA methylation pattern a§ novel 
marker for early detection of cervical cancer was reinforced. The two E2 binding 
sites, E2BS3 and E2BS4 within the promoter region, are potential targets of 
marker development and deserved to be further investigated. Nevertheless, the 
fact that only a proportion of cancer samples showed HPV DNA methylation 
needs to be cautiously considered when applying in clinical settings. Further 
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studies using larger numbers of clinical samples should be performed to validate 
our observation. More robust and high-throughput methods for the detection of 
viral DNA methylation should be explored. 
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Appendix I: Nucleotide substitutions within LCR 
Cell lines/ clinical samples 
Reference A T G T C A A VC^^t；；： Xv^^'0：； 'A ^ G^'X^^^t：^ ； 
命 典 髮 梦 解 ， � � \ \ � � ys vV^ S SN S � � - � � • " � � �  ••X��� ^ .s'OSXX >.'0,. V � � � 
Cell lines 
CaSki - T - - G A T A - C 
SiHa T A - - - -
Cancer samples 
WBX 342 C C T C T C C - - - A C A - T 
WBX 366 T - - - - G - - A - - C -
WBX 492 T A - - - -
WBX 530 C C T C T C C - - A C A - T 
WBX 630 C C T C T C C - - - A C A - T 
WBX 665 C C T C T C C - - - A C A - T 
WBX 666 C C T C T T C - - - A C A - T 
WBX 692 C C T C T C C - - - A C A - T 
WBX 755 C C T C T C - - - - A C A - T 
WBX 922 C C T C T C C - - - A C A - T 
WBX 991 C C T C T C C - A C A - T 
WBX 1114 C C T C T C C - A C A - T 
WBX 1120 C C T C T C - - A C A - T 
WBX 1143 C C T C T C C - A C A - T 
� WBX 1149 T A - - - -
WBX 1258 
WBX 1570 C C T C T C C - A C A - T 
WBX 1579 C C T C T C C - A C A - T 
WBX 1604 C C T C T C T - - A C A - T 
WBX 1605 C C T C T C - - A C A - T 
WBX 1606 C C T C T C C - A C A - T 
WBX 1607 C C T C T C - - - A C A - T 
WBX 1660 
Low-grade samples 
CS2082 T A - - - -
CS2156 T A - - - -
CS4345 T A - - - -
CS4603 C C T C T C C - A C A - T 
QE188 C C T C T C T - A C A - T 
QE196 T A - - - -
QE509 T A - - - -
QE516 -
QE651 C C T C T C C - A C A - T 
QE683 C C T C T C C - A C A - T 
QE946 C C T C T C C - - A C A - T 
QE075 C C T C T C C - A C A - T 
QE1123 - - T A - - - -
QE1916 T A - - - -
QE1917 C C T C T C C - A C A - T 
QE2397 C C T C T C C - - - A C A - T 
QE3954 C C T C T C C - A C A - T 
H140 T A - - - -
142 
W8687 C C T C T C - - - - A C A - T 
W8898 C C T C T C C - - A C A - T 
HPV16R was used as a reference sequence. Nucleotide positions with variations 
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